Literature DB >> 20307719

Bone marrow transplantation for primary immunodeficiency diseases.

Paul Szabolcs1, Marina Cavazzana-Calvo, Alain Fischer, Paul Veys.   

Abstract

Advances in immunology have led to a breathtaking expansion of recognized primary immunodeficiency diseases (PID) with over 120 disease-related genes identified. In North America alone more than 1000 children have received allogeneic blood or marrow transplant over the past 30 years, with the majority surviving long term. This review presents results and highlights challenges and notable advances, including novel less toxic conditioning regimens, to transplant the more common and severe forms of PID. HLA-matched sibling donors remain the ideal option, however, advances in living donor unrelated HSCT and banked umbilical cord blood grafts provide hope for all children with severe PID. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20307719     DOI: 10.1016/j.pcl.2009.12.004

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  16 in total

1.  Immune reconstitution after HSCT in SCID-a cohort of conditioned and unconditioned patients.

Authors:  Uri Manor; Atar Lev; Amos J Simon; Daphna Hutt; Amos Toren; Bella Bielorai; Lior Goldberg; Tali Stauber; Raz Somech
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

Review 2.  History and current status of newborn screening for severe combined immunodeficiency.

Authors:  Antonia Kwan; Jennifer M Puck
Journal:  Semin Perinatol       Date:  2015-04-30       Impact factor: 3.300

3.  HLA*IMP--an integrated framework for imputing classical HLA alleles from SNP genotypes.

Authors:  Alexander T Dilthey; Loukas Moutsianas; Stephen Leslie; Gil McVean
Journal:  Bioinformatics       Date:  2011-02-07       Impact factor: 6.937

4.  Use of TCR α+β+/CD19+-Depleted Haploidentical Hematopoietic Stem Cell Transplant Is a Viable Option in Patients With Primary Immune Deficiency Without Matched Sibling Donor.

Authors:  Tim Brettig; Joanne Smart; Sharon Choo; Francoise Mechinaud; Richard Mitchell; Trisha Soosay Raj; Theresa Cole
Journal:  J Clin Immunol       Date:  2019-06-06       Impact factor: 8.317

5.  Tolerance and immunity after sequential lung and bone marrow transplantation from an unrelated cadaveric donor.

Authors:  Paul Szabolcs; Rebecca H Buckley; Robert Duane Davis; Jerelyn Moffet; Judith Voynow; Jeyaraj Antony; Xiaohua Chen; Gregory D Sempowski; David W Zaas
Journal:  J Allergy Clin Immunol       Date:  2014-09-26       Impact factor: 10.793

Review 6.  Bone marrow transplantation in Schimke immuno-osseous dysplasia.

Authors:  Alireza Baradaran-Heravi; Jonas Lange; Yumi Asakura; Pierre Cochat; Laura Massella; Cornelius F Boerkoel
Journal:  Am J Med Genet A       Date:  2013-08-15       Impact factor: 2.802

7.  A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.

Authors:  Suhag H Parikh; Adam Mendizabal; Cara L Benjamin; Krishna V Komanduri; Jeyaraj Antony; Aleksandra Petrovic; Gregory Hale; Timothy A Driscoll; Paul L Martin; Kristin M Page; Ketti Flickinger; Jerelyn Moffet; Donna Niedzwiecki; Joanne Kurtzberg; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

8.  Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency.

Authors:  Miriam Hetzel; Takuji Suzuki; Anna Rafiei Hashtchin; Paritha Arumugam; Brenna Carey; Marc Schwabbauer; Alexandra Kuhn; Johann Meyer; Axel Schambach; Johannes Van Der Loo; Thomas Moritz; Bruce C Trapnell; Nico Lachmann
Journal:  Hum Gene Ther Methods       Date:  2017-08-30       Impact factor: 2.396

9.  Otitis media in children with congenital immunodeficiencies.

Authors:  Simon Urschel
Journal:  Curr Allergy Asthma Rep       Date:  2010-11       Impact factor: 4.806

Review 10.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.